Milan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.
https://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.png00entherahttps://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.pngenthera2020-12-03 08:00:022020-12-03 08:44:30Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development
Milan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
https://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.png00entherahttps://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.pngenthera2020-07-28 09:00:032020-07-28 11:35:02Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
Enthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.
https://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.png00entherahttps://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.pngenthera2018-07-24 09:11:452020-07-28 11:24:58Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing
Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development
/in Press ReleasesMilan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.
Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
/in Press ReleasesMilan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing
/in Press ReleasesEnthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.